Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR3 | P22607 | 2/20 | 0.54 |
| ▸ | FGFR1 | P11362 | 14/20 | 0.49 |
| ▸ | PDGFRB | P09619 | 12/20 | 0.49 |
| ▸ | KDR | P35968 | 12/20 | 0.49 |
| ▸ | FLT1 | P17948 | 4/20 | 0.49 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.42 |
| ▸ | TPH1 | P17752 | 1/20 | 0.42 |
| ▸ | TPH2 | Q8IWU9 | 1/20 | 0.42 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30424992 | 1.00 | FGFR3 (0.54) | FGFR3FGFR1PDGFRBKDRFLT1 | |
| SCHEMBL28399198 | 1.00 | FGFR3 (0.54) | FGFR3FGFR1PDGFRBKDRFLT1 | |
| SCHEMBL20624918 | 0.93 | FGFR3 (0.53) | FGFR3FGFR1PDGFRBKDRFLT1 | |
| SCHEMBL30425161 | 0.93 | FGFR3 (0.53) | FGFR3FGFR1PDGFRBKDRFLT1 | |
| SCHEMBL23326087 | 0.93 | FGFR3 (0.53) | FGFR3FGFR1PDGFRBKDRFLT1 | |
| SCHEMBL20624922 | 0.91 | FGFR3 (0.56) | FGFR3FGFR1PDGFRBKDRFLT1 | |
| SCHEMBL23326104 | 0.90 | FGFR3 (0.46) | FGFR3FGFR1PDGFRBKDRFLT1 | |
| SCHEMBL23326256 | 0.88 | FGFR3 (0.68) | FGFR3FGFR1PDGFRBKDRFLT1 | |
| SCHEMBL23326078 | 0.88 | FGFR1 (0.62) | FGFR3FGFR1PDGFRBKDRFLT1 | |
| SCHEMBL20625616 | 0.88 | FGFR1 (0.62) | FGFR3FGFR1PDGFRBKDRFLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111032643-B | Quinolinone compounds | 詹森药业有限公司 | 2023-05-30 | — | — | CN | disclosed |
| US-11384075-B2 | Quinolinone compounds | JANSSEN PHARMACEUTICA NV (BE) | 2022-07-12 | — | — | US | disclosed |
| US-20210139470-A1 | New Quinolinone Compounds | JOHNSON & JOHNSON (CHINA) INVESTMENT LTD. (CN) | 2021-05-13 | — | — | US | disclosed |
| CN-111032643-A | Quinolinone compounds | 詹森药业有限公司 | 2020-04-17 | — | — | CN | disclosed |
| WO-2019001419-A1 | NEW QUINOLINONE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2019-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210139470-A1 | New Quinolinone Compounds | FGFR1, FGFR2, FGFR3 | FGFR3 3/4885FGFR1 1/4885PDGFRB 31/4885 |
| US-11384075-B2 | Quinolinone compounds | FGFR1, FGFR2, FGFR3 | FGFR3 3/4885FGFR1 1/4885PDGFRB 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.